✦ LIBER ✦

Refractory leukemia treated with cytosine arabinoside and cyclophosphamide

✍ Scribed by B. M. Ansari; E. N. Thompson

Book ID: 101321753
Publisher: John Wiley and Sons
Year: 1973
Tongue: English
Weight: 283 KB
Volume: 32
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(197308)32:2<294::aid-cncr2820320203>3.0.co;2-x

No coin nor oath required. For personal study only.

✦ Synopsis

Eleven patients with acute leukemia (acute lymphatic leukemia 8, acute myeloid leukemia 3) were treated with cytosine arabinoside and cyclophorphamide; two also received asparaginase and two others prednisone. Nine of them had refractory disease in which reinduction with vincristine and prednisone had failed; two others were unable to tolerate vincristine and so this drug was not used again. In 7 of the 11 patients (acute lymphatic leukemia 5, acute myeloid leukemia 2), a complete remission was readily achieved. We suggest that this combination therapy is effective and should be considered as an alternative to vincristine and prednisone when these drugs are no longer beneficial particularly in acute lymphatic leukemia.

📜 SIMILAR VOLUMES

Cyclophosphamide, cytosine arabinoside a

Cyclophosphamide, cytosine arabinoside and methotrexate versus cytosine arabinoside and thioguanine for acute non-lymphocytic leukemia in adults

✍ Roland T. Skeel; William Costello; John M. Bennett; Martin M. Oken; Mark S. Tobi 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 720 KB

High dose cytosine arabinoside (HDARAC)

High dose cytosine arabinoside (HDARAC) in refractory acute leukemia

✍ Seth A. Rudnick; Edwin C. Cadman; Robert L. Capizzi; Roland T. Skeel; Joseph R. 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 415 KB 👁 2 views

Thirteen leukemic patients with disease refractory to conventional chemotherapy were treated with 1.0 to 7.5 g/m2 of Cytosine Arabinoside (Ara-C) over 29 drug cycles. Drug infusions were spaced at 12-hour intervals; a maximum of four doses was administered over 36 hours. After single dose tolerance

Cytosine arabinoside and 6-thioguanine i

Cytosine arabinoside and 6-thioguanine in refractory acute lymphocytic leukemia

✍ Dr. J. Hugh Bryan; Edward S. Henderson; Brigid G. Leventhal 📂 Article 📅 1974 🏛 John Wiley and Sons 🌐 English ⚖ 478 KB 👁 2 views

Sequential high-dose cytosine arabinosid

Sequential high-dose cytosine arabinoside and asparaginase in refractory acute leukemia

✍ Capizzi, Robert L. ;Cheng, Yung-Chi 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 551 KB

The development of resistance to Ara-C by leukemia cells may be a multifactorial process. These include diminished rates of anabolism or increased rate of catabolism to Ara-C, competition for incorporation into DNA by higher pool size of the competing normal metabolite, dCTP and perhaps other mechan

Mitoxantrone and high-dose cytosine arab

Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia

✍ Ronald S. Walters; Hagop M. Kantarjian; Michael J. Keating; William K. Plunkett; 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 547 KB

Forty-four patients with a diagnosis of refractory or relapsed acute myelogenous leukemia received salvage chemotherapy with high-dose cytosine arabinosine 3 g/m2 intravenously over 2 hours every 12 hours for six doses and mitoxantrone 5 mg/m2 intravenously daily for 5 days. Overall 16 patients (36%

Improved survival in young children with

Improved survival in young children with acute granulocytic leukemia treated with combination therapy using cyclophosphamide, oncovin, cytosine arabinoside, and prednisone

✍ Faris F. Madanat; Margaret P. Sullivan 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 386 KB 👁 2 views